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Abstract
Background
An inefficient immune response against Epstein-Barr virus (EBV) infection is related to the
pathogenesis of a subgroup of classical Hodgkin lymphomas (cHL). Some EBV immune-
evasion mechanisms target HLA presentation, including the non-classical HLA-E molecule.
HLA-E can be recognized by T cells via the TCR, and it also regulates natural killer (NK) cell
signaling through the inhibitory CD94/NKG2A receptor. Some evidences indicate that EBV-
infected B-cells promote the proliferation of NK subsets bearing CD94/NKG2A, suggesting
a relevant function of these cells in EBV control. Variations in CD94/NKG2A-HLA-E interac-
tions could affect NK cell-mediated immunity and, consequently, play a role in EBV-driven
transformation and lymphomagenesis. The two most common HLA-E alleles, E*01:01
and E*01:03, differ by a single amino acid change that modifies the molecule function. We
hypothesized that the functional differences in these variants might participate in the patho-
genicity of EBV.
Aim
We studied two series of cHL patients, both with EBV-positive and-negative cases, and a
cohort of unrelated controls, to assess the impact of HLA-E variants on EBV-related cHL
susceptibility.
PLOS ONE | DOI:10.1371/journal.pone.0135512 August 11, 2015 1 / 13
OPEN ACCESS
Citation: Martín P, Krsnik I, Navarro B, Provencio M,
García JF, Bellas C, et al. (2015) HLA Allele E01:01
Is Associated with a Reduced Risk of EBV-Related
Classical Hodgkin Lymphoma Independently of HLA-
A01/02. PLoS ONE 10(8): e0135512. doi:10.1371/
journal.pone.0135512
Editor: Joseph S Pagano, The University of North
Carolina at Chapel Hill, UNITED STATES
Received: February 12, 2015
Accepted: July 22, 2015
Published: August 11, 2015
Copyright: © 2015 Martín et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by Miguel Servet
programs CP09/00182 (NGL) and CP08/00218 (PM)
and the Spanish Cancer Network (RTICC RD 06/
0020/0047) all from Instituto de Salud Carlos III
(FEDER). The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Results
We found that the genotypes with at least one copy of E*01:01 (i.e., E*01:01 homozygous
and heterozygous) were underrepresented among cHL patients from both series compared
to controls (72.6% and 71.6% vs 83%, p = 0.001). After stratification by EBV status, we
found low rates of E*01:01-carriers mainly among EBV-positive cases (67.6%). These
reduced frequencies are seen independently of other factors such as age, gender, HLA-
A*01 and HLA-A*02, HLA alleles positively and negatively associated with the disease
(adjusted OR = 0.4, p = 0.001). Furthermore, alleles from both HLA loci exert a cumulative
effect on EBV-associated cHL susceptibility.
Conclusions
These results indicate that E*01:01 is a novel protective genetic factor in EBV-associated
cHL and support a role for HLA-E recognition on the control of EBV infection and
lymphomagenesis.
Introduction
Epstein-Barr virus (EBV) is a ɣ-herpesvirus with a high prevalence worldwide (over 90%)
which interacts with the host immune system and typically establishes benign lifelong latent
infection in the B-cells of healthy immunocompetent individuals [1]. However, in some cases,
the normal homeostasis of the EBV-specific response is disrupted and leads to the malignant
transformation of the infected cells. EBV-driven oncogenesis is related to the development
of a subset of several B-cell lymphomas in immunocompetent individuals (mainly, Burkitt
[BL], diffuse large B cell [DLBCL] and classical Hodgkin’s [cHL] lymphomas) and in immuno-
compromised patients (post-transplant [PTLD] and HIV-associated lymphoproliferative
disorders).
The relationship between EBV infection and cHL is well established. The rates of EBV-
related cHL vary by ethnic group, age, gender, socio-economic status, and histological subtype,
and its development is associated with a previous history of infectious mononucleosis [2]. The
epidemiology of EBV suggests a complex interplay between genetic, viral and environmental
factors that converge to an inadequate immune control of EBV infection. However, genetic
drivers of EBV-specific immune responses and lymphomagenesis in EBV-related cHL remain
unclear.
There is increasing evidence that the NK cell repertoire plays a role in EBV-directed immu-
nity. In this way, NK cells exhibit greater cytotoxicity during acute EBV infection, and in a
humanized mouse model, NK cells limit the EBV viral load, infectious mononucleosis symp-
toms, and tumor formation [3–5]. Their significance in the control of EBV infection is sup-
ported by the observation that primary immunodeficiencies affecting NK cells or NK cell
recognition of EBV-transformed cells are associated with EBV-positive malignancies and fatal
EBV infection [6–8].
Recently, an EBV-driven imprint on the NK compartment has been reported and is charac-
terized by the proliferation of an NK cell population expressing the inhibitory receptor CD94/
NKG2A (CD56dimNKG2A+KIR-CD57-) in tissues and peripheral blood during acute symp-
tomatic infection [9, 10]. Moreover, a CD56bright NK cell subset with a similar NKG2A+
phenotype proved to be relevant for controlling infection in the tonsils and to have the
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potential to inhibit in vitro EBV-induced transformation [11]. These findings support a role
for CD94/NKG2A-HLA-E signaling in NK-mediated control of EBV and its associated
pathologies.
The inhibitory CD94/NKG2A receptor, a member of the heterodimeric CD94/NKG2 fam-
ily, is expressed on NK and CD8+ T cell subsets. This receptor interacts with a high affinity
and in a peptide-specific manner with the non-classical class I molecule HLA-E loaded with
signal peptides derived from other HLA-I molecules [12, 13]. The CD94/NKG2A-HLA-E
interaction constitutes a sensor that monitors HLA class I expression on healthy cell surfaces
and provides an immunomodulatory mechanism of tolerance. HLA‐E can also present stress-
or pathogen-derived peptides (including EBV), whether to CD94/NKG2A or TCR bearing
cells, to survey cellular stress or infection by NK and T cells [14–16].
Expression of HLA molecules on infected cells varies during the EBV cycle infection and
inversely correlates with sensitiveness to NK killing. Latently EBV-infected B-lymphoblastoid
cell lines (B-LCLs) express high levels of HLA molecules, and resist NK lysis [3, 17]; however,
HLA class I expression is down-modulated upon entry into the lytic cycle, which is associated
with an increase of the NK cell response [18, 19]. HLA class I antigens synthesis and assembly
pathways are disrupted in a concerted manner by several EBV antigens (e.g., BNLF2a, BGLF5,
BILF1, vIL10) during the lytic cycle, which affects and targets a broad range of HLA antigens
[20–22]. HLA-E expression is also affected by EBV immune-evasion mechanisms, presumably
circumventing the recognition of HLA-E-viral peptide complexes by CD8+ T cells [23].
Compared to the characteristic genetic diversity of classical class IMHC genes, HLA-E is
fairly conserved. The low level of HLA-E polymorphism was present before the generation of
classical HLA diversity and seems to be driven by a different selective pressure. These features
suggest an essential function for this molecule [24, 25]. Fifteen different HLA-E nucleotide
sequences have been described to encode two different protein sequences: E01:01 and E01:03
(http://www.ebi.ac.uk/ipd/imgt/hla [26]). These two HLA‐E molecules are present in more
than 90% of the population with similar frequencies, suggesting that balancing selection is act-
ing on the dimorphism [27]. Both variants differ at only one non-synonymous substitution
(1147A>G; rs1264457) that results in an amino acid change (arginine to glycine) at position
107 in the alpha-2 domain of the heavy chain. This substitution confers different levels of sur-
face expression and peptide affinities. E01:03 is expressed at higher levels than E01:01, proba-
bly due to an increase in peptide binding ability that results in a more stable configuration [28].
The allelic diversity ofHLA-E is associated to several clinical situations. In HCV infection,
the homozygous E01:03 genotype seems to correlate with chronification [29], and in hemato-
poietic stem cell transplantation, it has been shown to confer protection against graft‐versus‐
host disease, leukemia relapse and mortality [30–32]. Other investigators have reported that
the E 01:01 allele associates with recurrent miscarriage [33] and a reduced risk of Behcet’s
disease [34].
We performed a case-control study to evaluate whether the genetic diversity ofHLA-E
affects susceptibility to lymphomagenesis in cHL and its relationship to EBV infection.
Materials & Methods
Ethics Statement
The project was approved by the Ethics Committee of Hospital Puerta de Hierro (Approval
number: Acta n° 304). Written informed consent was provided by all of the patients and
controls.
HLA-E Genetics in EBV-Positive Hodgkin Lymphoma
PLOSONE | DOI:10.1371/journal.pone.0135512 August 11, 2015 3 / 13
Patients and clinicopathological data
One hundred and seventy-five patients diagnosed of cHL (73 EBV+ and 102 EBV-) and 400
unmatched healthy individuals from Hospital Puerta de Hierro Majadahonda (Madrid, Spain)
were enrolled in this study. Another series of 82 patients diagnosed with cHL (35 EBV+ and 47
EBV-) from MD Anderson Cancer Center (Madrid, Spain) were studied to validate the results.
cHL was diagnosed based on a morphological and immunohistochemical examination of
biopsy materials using standard techniques. The histopathological classification and cHL sub-
classification were based on the World Health Organization (WHO) 2008 criteria as follows:
nodular sclerosis (NS), mixed cellularity (MC), lymphocyte-rich (LR), lymphocyte-depleted
(LD) or not classified (NC) cHL. HIV-positive patients were excluded from the study.
Nuclear staining of HRS by in-situ hybridization for EBERs using the Bond ISH EBV-EBER
probe was used to detect EBV-infection in the cells. The main characteristics of the cHL patient
are summarized in Table 1, and the other clinico-pathological parameters of the patients are
shown in S1 Table.
HLA typing
DNA was extracted from either peripheral blood with DNAzol (MRC, Cincinnati, OH) or
using a Maxwell 16 Blood DNA purification kit (Promega Corp. Madison, CA); or from the
paraffin-embedded tissue of biopsied tumoral lymph nodes using the QIAmp DNA FFPE Tis-
sue Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions.
HLA-E typing discriminating the single nucleotide polymorphism in codon 107 (A>G) was
performed using PCR-SSP as described [35] with minor modifications. To validate the geno-
typing method, reference DNAs from the IHW cell panel were used. Randomly selected sam-
ples and problematic DNAs were examined by DNA sequencing in a 3130xl Genetic Analyzer
Sequencer (Applied Biosystems, Foster City, CA, USA) using the amplification primers HLA-
E_Fcon290 5’-ACCGCACAGATTTTCCGAGT-3’ and HLA-E_Rcon396 5’-AGGCGAACTG
TTCATACCCG, with HLA-E_Fi6 5’-TCAGTTTAGGCCAAAATGCCCA-3’ as an internal
primer for sequencing.HLA-A01 and A02 typing was performed by PCR-SSP with the
primer pairs FHc527 5’-TGGGAGGCGGTCCATGC-3’ and Rhcg570 5’-AGGTATCTGCGG
AGCCCG-3’ for A01, and FHa144 5’-GAGCCCCGCTTCATCGCA-3’ and RHagg256 5´-TT
CACTTTC CGTGTCTCCCC-3’ for A02 (details available upon request).
Table 1. Characteristics of the cHL patients and control subjects.
% (N) All cHL (N = 257) EBV+ cHL (N = 108) EBV- cHL (N = 149) Controls (N = 400)
HPH (N = 175) MDA (N = 82) HPH (N = 73) MDA (N = 35) HPH (N = 102) MDA (N = 47)
Male gender 56.8 (107) 56.8 (46) 79.5 (58) 57.1 (20) 48.0 (49) 55.3 (26) 47.5 (190)
Age <45 years 69.7 (122) 64.2 (52) 52.1 (38) 51.4 (18) 82.4 (84) 72.3 (34) 60.3 (240)
Histological subtype
NS 60.6 (106) 61.0 (50) 43.8 (32) 45.7 (16) 72.5 (74) 72.3 (34)
MC 30.3 (53) 29.3 (24) 45.2 (33) 37.1 (13) 19.6 (20) 23.4 (11)
Other 4.6 (8) 3.7 (3) 5.5 (4) 8.6 (3) 3.9 (4) 0
NC 4.6 (8) 6.1 (5) 5.5 (4) 8.6 (3) 3.9 (4) 4.3 (2)
HPH, patients from the Hospital Puerta de Hierro. MDA, patients from MD Anderson Cancer Center. NC: not classiﬁed.
doi:10.1371/journal.pone.0135512.t001
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Statistical Analysis
Differences in the distribution of HLA-E genotypes reported in this study were calculated using
the Pearson χ2 test and considering a dominant model for the protective allele HLA-E01:01
(E01:01 carriers vs negatives). In both the control and patient groups, HLA-E genotypes were
evaluated for adequacy to Hardy-Weinberg equilibrium.
Odds ratio (OR) values and 95% confidence intervals (CIs) for relative risks were calculated
for the genotypes. Frequencies of combined HLA-A-HLA-E phenotypes were compared with
Pearson χ2 test or Fisher’s test when any expected frequency was lower than five individuals.
Linkage disequilibrium (LD) between HLA-E alleles and A01 and A02 was measured by coef-
ficient D’ (D/Dmax). The confounding effect of gender and age was analyzed by a stratified
analysis of the association ofHLA-E genotypes with the risk of cHL (male, female,<45 years
and 45 years subgroups). Multiple logistic regression was performed to measure the inde-
pendent contribution ofHLA-E genetics and other associatedHLA variables (A01 and A02)
on the risk of EBV-positive cHL. Data were analyzed using the Statistical Package for the Social
Sciences software (SPSS 15, Chicago, IL, USA).
Results
Characteristics of cHL patients
One hundred and seventy-five Spanish patients with cHL from Hospital Puerta de Hierro
(Madrid) and 400 unmatched healthy individuals from the same area were included in the
study. The characteristics of the cHL cohort (Table 1 and S1 Table) were consistent with its epi-
demiology in Western Europe [36, 37]. The histological distribution was as follows: 60.6%
(n = 106) of the cases were NS subtype, followed by a 30.3% (n = 53) with MC histology, 4.6%
(n = 8) corresponded to other less frequent subtypes (LD and LR), and 4.6% (n = 8) were not
histologically classified.
Consistently with other series [38, 39], 41.7% of the cHL patients were EBV-positive with a
bimodal age-incidence curve (data not shown) and the presence of EBV was more frequent in
males (79.5% males vs 20.5% females, p = 2.6x10-5). Additionally, 64.7% and 30.2% of the MC
and NS cases were EBV-positive. The EBV-negative lymphomas presented a unimodal age dis-
tribution, were predominantly found in young adults aged<45 years, lacked an association
with gender, and the majority had a NS histology (75.5%).
As a replicative series of cHL, we studied 82 patients from a different medical Center in
Madrid (MD Anderson Cancer Center, Spain). Clinical and biological data were very similar to
the results obtained in our exploratory series, including epidemiology, EBV association and
histology, as shown in Table 1 and S1 Table.
HLA-E distribution in controls and cHL patients
Analysis of the HLA-E genotype distribution in healthy controls (S2 Table) showed that the
majority of the individuals (49.6%) were heterozygous at the dimorphism (E01:01, 01:03). The
major (E01:01) and minor (E01:03) homozygous genotypes were present in 33.3% and 17%
of the individuals, respectively. HLA-E allelic and genotypic frequencies fell into the range
reported for other European ancestry reference populations from The 1000 genomes project
(http://www.1000genomes.org: CEU, TSI, GBR and FIN) and from other reported population
studies [40].
The distribution of theHLA-E genotypes in the cHL cohort (regardless of the EBV status),
as well as in all the EBV-categorized subgroups, was closely replicated in both series (S2 Table):
Hospital Puerta de Hierro (HPH) and MD Anderson Cancer Centre (MDA). The consistency
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of the results obtained in the two cohorts supports the validity of our data and, additionally, it
permitted to compile and analyze both series together to strengthen the statistical power of the
study. The genotype frequencies of HLA-E in controls and patients were consistent with
Hardy-Weinberg equilibrium.
HLA-E*01:01 is a protective factor in cHL and its negative association is
mainly derived from EBV-positive cases
In cHL patients (either with a positive or a negative EBV status) E01:01 was less frequent
compared to controls (individuals with the E01:01 allele, 72.4% vs 83%; Table 2; OR 0.5,
p = 0.001). To assess the selective effect of HLA-E on the risk of EBV-driven lymphomagenesis,
EBV-positive and EBV-negative tumors were analyzed separately. Only 67.6% of the EBV-
positive cases were homozygous or heterozygous for the E01:01 allele, which indicated
that E01:01-carriers have a significantly decreased risk of EBV-associated cHL (OR = 0.4,
p = 0.0004, Table 2). EBV-negative patients had an intermediate frequency of E01:01 (75.8%),
and showed a non-significant tendency toward a decreased frequency in comparison to con-
trols (OR = 0.6, p = 0.057). This reduction of E01:01 frequency in EBV-negative cases is mod-
erate compared to EBV-positive patients cases and our study lacks sufficient statistical power
to determine significant differences between these two subgroups (p = 0.15). These results indi-
cated that the reduction of E01:01-carriers in the global cohort of cHL patients (irrespective of
the EBV status) is attributable to differences in the distribution ofHLA-E genotypes in the
EBV-positive subgroup.
We analyzed the potential effect of the E01:01 allele dose on the decreased risk of EBV-pos-
itive cHL. Similar OR values were obtained for carriers of one (OR = 0.4, p = 0.002) or two cop-
ies (OR = 0.4, p = 0.002) of E01:01 compared to donors lacking the protective allele, indicating
that the risk of suffering from EBV-positive cHL does not depend on the E01:01 allele dosage.
The association of HLA-E*01:01 with EBV-positive cHL is not influenced
by age or gender
We stratified the series by gender and age, variables previously associated with EBV-associated
cHL, to investigate their possible confounding effect on the contribution of theHLA-E
Table 2. Analysis of theHLA-E*01:01 allele as a protective factor in cHL stratified by EBV status.
E*01:01 carriers % (N)a OR (95% CI) χ2 p-value
Controls (N = 400) 83.0 (332)
EBV+ cHL HPH (N = 73) 68.5 (50) 0.5 (0.3–0.8) 0.0038
MDA (N = 35) 65.7 (23) 0.4 (0.2–0.8) 0.011
All (N = 108) 67.6 (73) 0.4 (0.2–0.7) 0.0004
EBV- cHL HPH (N = 102) 75.5 (77) 0.63 (0.4–1.1) 0.081
MDA (N = 47) 76.6 (36) 0.7 (0.3–1.4) 0.28
All (N = 149) 75.8 (113) 0.64 (0.4–1.0) 0.057
Total cHL HPH (N = 175) 72.6 (127) 0.5 (0.4–0.8) 0.0042
MDA (N = 82) 71.6 (59) 0.5 (0.3–0.9) 0.02
All (N = 257) 72.4 (186) 0.5 (0.4–0.8) 0.001
HPH: patients from Hospital Puerta de Hierro, MDA: patients from MD Anderson Cancer Center
OR: odds ratio; CI, conﬁdence interval
a Genotypes with the protective allele (homozygous E*01:01 and heterozygous)
doi:10.1371/journal.pone.0135512.t002
HLA-E Genetics in EBV-Positive Hodgkin Lymphoma
PLOSONE | DOI:10.1371/journal.pone.0135512 August 11, 2015 6 / 13
genotype to the risk of developing EBV-associated cHL. The subgroup analysis showed that
E01:01 was similarly associated in males and females (OR = 0.4, p = 0.0037 and OR = 0.4,
p = 0.028; respectively) and in<45 years old (OR = 0.5, p = 0.021) versus45 years old
(OR = 0.4, p = 0.009) categories (Table 3). This analysis confirmed that the negative association
between the E01:01 allele and the risk of EBV-positive cHL was not influenced by age or gen-
der. Similarly, stratifications of the EBV-positive cHL series by histology and other clinical
parameters (disease stage, presence of bulky tumor and survival) did not reveal any differences
in the distribution of theHLA-E genotypes (data not shown).
Analysis of HLA-E/HLA-A interaction: Identification of HLA-E/HLA-A
phenotypes associated to the EBV-positive cHL susceptibility
HLA alleles A01 and A02 have been reported to associate with an increased and a reduced
risk of EBV-positive cHL, respectively [41, 42]. In our study, A01 and A02 in healthy controls
had similar frequencies to those reported for Spanish population (A01: 16.8% and A02:
51.9%) [43] and consistent with previous works, in the EBV-positive cHL cohort, A01 is of
risk (43.2%, OR = 3.8, p = 2.3x10-8) whilst A02 is protective (31.9%, OR = 0.4, p = 0.001).
Given the strong LD in theHLA region and the vicinity ofHLA-A and -E loci, we analyzed
the genetic association ofHLA-E alleles and A01 and A02, in order to study their interaction
and relative contribution to EBV-positive cHL. The LD analysis within our control samples
showed that the predisposing A01 allele was in strong positive LD with the protective E01:01
allele (D’ = 0.65, p = 0.0082) and in weaker, non-significant negative LD with the risk E01:03
allele (D’ = −0.13, p = 0.096). On the contrary, the protective A02 presented a random associa-
tion with the protective E01:01 (D’ = −0.05, p = 0.64) and a weak LD with the risk E01:03
(D’ = 0.15, p = 0.026).
Strikingly, in patients, HLA-A and HLA-E alleles with opposed effects on the risk of the
EBV-related cHL had a lower LD compared to those described for controls. We found a
decreased non-significant LD between the protective E01:01 and the predisposing A01 (D’ =
0.34, p = 0.064) and no association between the risk E01:03 and the protective A02 (D’ =
0.02, p = 0.86). These reduced LD between HLA-A andHLA-E alleles with a confronting influ-
ence on EBV-associated cHL risk would indicate a selection ofHLA phenotypes composed by
predisposing HLA-A andHLA-E alleles in EBV-positive cHL patients.
Table 3. Stratification of HLA-E*01:01 frequency for age and gender.
Variable Subjects E*01:01 allele % (N) OR (95% CI) χ2 p-value
Gender
Male EBV+ cHL (N = 78) 73.1 (57) 0.4 (0.2–0.74) 0.0037
Controls (N = 193) 87.6 (169)
Female EBV+ cHL (N = 30) 53.3 (23) 0.4 (0.21–0.92) 0.028
Controls (N = 212) 78.7 (167)
Age (years)
<45 EBV+ cHL (N = 56) 69.6 (39) 0.5 (0.24–0.9) 0.021
Controls (N = 243) 83.1 (202)
45 EBV+ cHL (N = 55) 65.4 (34) 0.4 (0.2–0.8) 0.009
Controls (N = 160) 82.6 (132)
OR: odds ratio; CI, conﬁdence interval
doi:10.1371/journal.pone.0135512.t003
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A subgroup analysis stratified byHLA-A alleles revealed a similar distribution of E01:01
in A01-carriers (OR = 0.3, p = 0.029) and in A01-negative donors (OR = 0.4, p = 0.003);
and, similarly, in A02-positive (OR = 0.4, p = 0.036) or A02-negative subjects (OR = 0.6,
p = 0.088). In A01 A02 double negative subjects, E01:01 also presents comparable frequen-
cies, but sample size is not large enough to detect significant differences (80.5% vs. 68.6%;
OR = 0.5, p = 0.17). These results indicate that A01 and A02 alleles are not confounding fac-
tors influencing the protective association between the E01:01 allele and the risk of EBV-posi-
tive cHL.
A multiple logistic regression analysis was performed to further assess the possible influence
of A01 and A02 on the association ofHLA-E to the risk of EBV-related cHL (Table 4). After
adjusting by presence ofHLA-A01 and A02, E01:01 remained as a significant protective fac-
tor. This analysis confirmed that E01:01 is negatively associated with the risk of EBV-positive
cHL (OR = 0.4, p = 0.001) and this association is independent of other known HLA factors that
impact on the risk of EBV-related cHL.
Finally, we examined the cumulative effect of theHLA-A and-E polymorphism on the risk
of EBV-positive cHL through the comparison of protective phenotypes (E01:01+ve, A01-ve or/
and A02+ve) to all other phenotypes or to its opposite risk phenotype (E01:01-ve, A01+ve or/
and A02-ve) (Table 5). ProtectiveHLA-E-HLA-A combinations were dominant in healthy con-
trols but clearly underrepresented in EBV-associated cHL (E01:01+veA01-ve: 67.2% vs 35.8%,
E01:01+veA02+ve: 42.6% vs 20.9% and E01:01+veA01-veA02+ve: 36.1% vs 9.5%). On the con-
trary, the reciprocal risk phenotypes had very low rates in healthy controls and were increased
in EBV-associated cHL (E01:01-veA01+ve: 1% vs 8.4%, E01:01-veA02-ve: 7.8% vs 16.8% and
Table 4. Multivariate logistic regression analysis: E*01:01 contributes independently of otherHLA
factors to the risk of EBV+ cHL.
Variable OR 95% CI p-value
E*01:01 positive 0.4 0.2–0.7 0.001
A*01 positive 3.9 2.3–6.5 6.7x10-7
A*02 positive 0.4 0.2–0.6 0.001
OR: odds ratio; CI, conﬁdence interval
doi:10.1371/journal.pone.0135512.t004
Table 5. Analysis of the combined effect ofHLA-E*01:01, A*01 and A*02 on the risk of EBV-associated cHL.
Protective phenotype EBV+ cHL %(N) Controls %(N) OR (95% CI) p-value
E*01:01+ve A*01-ve 35.8 (34) 67.2 (268)
vs opposite phenotype 8.4 (8) 1.0 (4) 0.06 (0.02–0.22) 0.0004
vs all other phenotypes 64.2 (61) 32.8 (131) 0.27 (0.17–0.44) <10−8
E*01:01+ve A*02+ve 20.9 (19) 42.6 (170)
vs opposite phenotype 16.8 (16) 7.8 (31) 0.22 (0.10–0.47) 3.4x10-5
vs all other phenotypes 79.1 (72) 57.4 (229) 0.34 (0.20–0.58) 4.3x10-5
E*01:01+ve A*01-ve A*02+ve 9.5 (9) 36.1 (144)
vs opposite phenotype 5.3 (5) 0.3 (1) 0.013 (0.001–0.12) 2.9x10-5
vs all other phenotypes 90.5 (80) 63.9 (255) 0.18 (0.09–0.36) <10−8
OR: odds ratio; CI, conﬁdence interval
+ve: positive
-ve: negative
doi:10.1371/journal.pone.0135512.t005
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E01:01-veA01+veA02-ve: 0.3% vs 5.3%). In summary, comparison of the frequencies of the
protective HLA-A-HLA-E phenotypes to the frequencies of any other genotypes or their oppo-
site risk phenotypes showed a marked decrease on the risk of EBV-associated cHL, demon-
strating an additive effect of HLA-E and HLA-A genetics on protection against EBV-positive
cHL (e.g. OR = 0.013 for the E01:01+ve A01-ve A02+ve phenotype in comparison with its
reciprocal, p = 2.9x10-5).
Discussion
Inherited variations in host immune responses have long been associated with susceptibility or
protection against disease, including tumors and infections. We analyzed the contribution of
HLA-E genetics to the susceptibility of developing EBV-driven cHL in a case-control study.
Our results showed a reduced frequency of E01:01 in EBV-positive cHL cases compared to
controls. This difference indicated a protective effect of this variant─ E01:01-positive individ-
uals would have more than a 50% reduction in the risk of developing EBV-associated cHL. The
validity of this genetic association is strengthened by the replication of the HLA-E distribution
in a supplementary series of cHL patients in the same geographic region. We also found that
the association of HLA-E with EBV-positive cHL is not linked to other reported demographic
factors associated with this disease such as age and gender. The relationship of cHL resistance
to the E01:01 allele did not show a dose effect, likely implying a dominant influence of this var-
iant on protection against the disease.
A potential biological rationale for the genetic association with EBV-associated lymphomas
described herein could be the influence of HLA-E polymorphism on CD94/NKG2A signaling
in NK cells. In this model, it may be speculated that lower expression of HLA-E01:01 in EBV-
infected cells, as compared with E01:03, could confer an attenuated NKG2A-mediated inhibi-
tion of NK or CD8+ T cell killing. This phenomenon could be translated into an enhanced
EBV-directed cytotoxic response in E01:01 carriers that could contribute to protection against
a malignant course of EBV infection. Another hypothesis is that E01:01 could more efficiently
present EBV-derived peptides to CD8+ T lymphocytes than E01:03, generating an increased
cytotoxic T cell response to EBV infection.
In EBV-negative cHL, the frequency of E01:01 was intermediate between healthy controls
and EBV+ cases. Although we did not find significant differences because the reduction of the
frequency of the E01:01 allele was not as pronounced as that in the EBV+ group, the results
could also have a potential biological significance. HLA-E is expressed at high levels by some
tumors [44–46], including neoplastic and microenvironment cells in some cHL patients [47].
The expression and function of HLA-E in cancer cells is not fully understood, but it may repre-
sent a mechanism of tolerance that could be influenced byHLA-E polymorphism. Further
studies with larger cohorts should be performed to better estimate the relevance ofHLA-E
genetics in EBV-negative cHL.
One limitation of our study is that the control series could not be monitored for antibodies
against EBV. To assess how EBV-serostatus would impact on our results, we estimated, from
age-adjusted EBV-seroprevalence data of our Institution (Dr. Portero, F, Microbiology Depart-
ment; personal communication), a 4% of EBV IgG seronegative controls in our cohort. With
this seronegativity rate, and even in the worst scenario for our conclusions (i.e. subtracting 4%
[N = 25] supposed seronegatives only from the E01:01 carrier group), we estimated an irrele-
vant influence of EBV-seronegative subjects on our results (data not shown)
The influence of the HLA-E locus on the genetic background of EBV-induced tumors has
also been studied in nasopharyngeal carcinoma (NPC), an EBV-associated malignancy with a
restricted racial and geographical distribution. In Thai NPC patients, a homozygous E01:03
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genotype was associated with an increased risk of disease, i.e., E01:01-carriers were, as in this
study, protected for EBV-tumorigenesis [48]. However, although a similar trend was found in
Tunisian patients with NPC, neither HLA-E allele was found to have major effects on NPC sus-
ceptibility or progression [49].
Previous investigations on the association of the HLA class I region with EBV-associated
cHL pointed toHLA-A1 and A2 being positively and negatively associated, respectively, with
EBV+ cHL [47, 48]. The HLA-E locus is ~540 kb centromeric to HLA-A (http://vega.sanger.ac.
uk). The physical proximity of the two genes raised the question of whether the relationship
between HLA-E and EBV-positive cHL could be secondary to an association withHLA-A or
vice versa. Interestingly, we found that the association ofHLA-E with EBV-positive cHL is
independent of those of A01 or A02, which were replicated in our study. Despite the exten-
sive amount of studies assessing the LD in MHC region, few of them include data on HLA-E
polymorphism. These studies describe an essentially random association of their alleles, proba-
bly due to the presence of recombination hot spots [24] but also, some conserved HLA-A-
HLA-E haplotypes, including the combination of the EBV-positive Chl protective E01:01 and
the predisposing A01 [50]. Here, we found also this association between A01 and E01:01 in
healthy individuals. This haplotype, contradictory in terms of influence on EBV-positive cHL
risk, presents a lower LD among EBV-positive cHL patients in whom it is underrepresented.
An analysis integrating the effect of E01:01, A01 and A02 revealed the existence of protective
phenotypes by which E01:01-positive, A01-negative and A02-positive individuals would
have more than 70 times less risk of developing EBV-associated cHL than the opposite high-
risk phenotype (E01:01-negative, A01-positive and A02-negative). The high frequencies of
the protectiveHLA-A-HLA-E phenotypes and the low rates of the opposite risk phenotypes in
healthy individuals could indicate an EBV selective pressure shapingHLA-A andHLA-E poly-
morphism. Our results suggest a potential use of combined HLA-A and-E typing as a bio-
marker of increased risk of EBV-positive cHL
EBV-positive cHL presents an intrincate epidemiology, and the overall incidence rates vary
greatly in different regions of the world [36]. The origin of this geographic discrepancy is
unknown, but even when modifiable factors such as lifestyle or the environment are controlled
for epidemiological studies, some variability remains across the ethnic groups [51]. These per-
sistent differences in susceptibility to EBV-associated cHL among human populations might
be partially explained by polymorphic genetic systems that show ethnic variation in the rates of
allelic prevalence, such asHLA-E andHLA-A.
The association of theHLA-E genetic diversity with the susceptibility of EBV-driven cHL
suggests a role for the HLA-E molecule in the etiopathogenesis of the disease. These findings
may contribute to the understanding of the influence of host genetics on EBV-related
lymphomas.
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